Darren J. Walsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Darren J. Walsh has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Laura Jane Sahm
University College Cork
5 shared publications Michelle Hannan
University Hospital Waterford, Waterford, Ireland
5 shared publicationsAnne M. Horgan
University Hospital Waterford, Waterford, Ireland
4 shared publicationsMichelle O'DRiscoll
Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland
3 shared publicationsBronagh Bolger
Oncology Department, University Hospital Waterford, Waterford, Ireland
2 shared publicationsCaitriona Goggin
Oncology Department, University Hospital Waterford, Waterford, Ireland
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Taylor & Francis in Geriatric Pharmacology
- Vol. 3 (1)
Deprescribing practices in older adults with cancer: a narrative Review by the British Oncology Pharmacy Association Geriatric Oncology Specialist Advisory Group
Older adults with cancer can be burdened by complex medication regimens due to the need for systemic anti-cancer treatments (SACT), supportive medications, and drugs for managing comorbid condition...
- 12 August 2026
- Published by Taylor & Francis in Geriatric Pharmacology
- Vol. 3 (1)
Open AccessDeprescribing practices in older adults with cancer: a narrative Review by the British Oncology Pharmacy Association Geriatric Oncology Specialist Advisory Group
Older adults with cancer can be burdened by complex medication regimens due to the need for systemic anti-cancer treatments (SACT), supportive medications, and drugs for managing comorbid condition...
- 1 May 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (8) , 102368
The need to develop a clinical competency framework for hospital pharmacist education and training programmes in Irish hospital pharmacy
- 1 May 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (8) , 102368
The need to develop a clinical competency framework for hospital pharmacist education and training programmes in Irish hospital pharmacy
- 30 January 2025
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 19 (1) , 2-11
Medication management: supportive care medications in older adults with cancer
Purpose of review: This review raises awareness regarding the lack of data available for healthcare professionals caring for older adults with cancer when using supportive care medications. Recent findings: Guidelines for supportive cancer care lack concrete recommendations on the appropriate use of medications in older adults with cancer. Some guidelines, such as the National Comprehensive Cancer Network Older Adult Oncology guideline, contain vital information for prescribers to consider when choosing a supportive care medication. Information at present in most guidelines is generally vague, identifying areas where caution is required in older adults, without specific details. Summary: Research is needed to assess the efficacy and safety of supportive cancer care medications in older adults.
- 30 January 2025
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 19 (1) , 2-11
Medication management: supportive care medications in older adults with cancer
Purpose of review: This review raises awareness regarding the lack of data available for healthcare professionals caring for older adults with cancer when using supportive care medications. Recent findings: Guidelines for supportive cancer care lack concrete recommendations on the appropriate use of medications in older adults with cancer. Some guidelines, such as the National Comprehensive Cancer Network Older Adult Oncology guideline, contain vital information for prescribers to consider when choosing a supportive care medication. Information at present in most guidelines is generally vague, identifying areas where caution is required in older adults, without specific details. Summary: Research is needed to assess the efficacy and safety of supportive cancer care medications in older adults.
- Open Access
- 28 August 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (8) , e009258
Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022
Immune checkpoint inhibitors (ICI) have transformed the management of cancer, particularly for older adults, who constitute a majority of the global cancer patient population. This study aimed to assess the inclusion, characteristics, and reporting of older adults enrolled in Food and Drug Administration (FDA) registration clinical trials of ICI between 2018 and 2022. Clinical trials of ICI leading to an FDA approval in solid tumor oncology between 2018 and 2022 were included. Primary study reports and all available secondary publications were assessed. The availability and completeness of older subgroup data for protocol-defined clinical efficacy endpoints, health-related quality of life (HRQOL) and toxicity outcomes, and baseline characteristics were assessed according to predefined criteria which categorized reporting completeness hierarchically in relation to the availability of published data, including effect size, sample size, and measures of precision. 53 registration trials were included, involving a total of 37,094 participants. Most trials (64.2%) were of ICI combination therapy. 42.3% of patients were aged≥65 years; 11.1% were aged≥75. No trials specified an upper age limit for eligibility. 98.1% of trials excluded patients with European Cooperative Oncology Group performance status>1. 87.2% of primary efficacy endpoints and 17.9% of secondary efficacy endpoints were reported completely for older adults. Five studies (9.4%) reported baseline characteristics, three (6.1%) reported HRQOL assessments, and four (7.5%) reported toxicity outcomes completely among older subgroups. No trials conducted baseline geriatric assessments or reported geriatric-specific symptoms or quality of life scales. This analysis highlights significant deficits in the enrollment and reporting of older subgroups in pivotal trials of ICI therapy. The findings highlight an urgent need for improved reporting and inclusion standards in clinical trials of ICI to better inform treatment decisions for older adults.
- 28 August 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (8) , e009258
Open AccessInclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022
Immune checkpoint inhibitors (ICI) have transformed the management of cancer, particularly for older adults, who constitute a majority of the global cancer patient population. This study aimed to assess the inclusion, characteristics, and reporting of older adults enrolled in Food and Drug Administration (FDA) registration clinical trials of ICI between 2018 and 2022. Clinical trials of ICI leading to an FDA approval in solid tumor oncology between 2018 and 2022 were included. Primary study reports and all available secondary publications were assessed. The availability and completeness of older subgroup data for protocol-defined clinical efficacy endpoints, health-related quality of life (HRQOL) and toxicity outcomes, and baseline characteristics were assessed according to predefined criteria which categorized reporting completeness hierarchically in relation to the availability of published data, including effect size, sample size, and measures of precision. 53 registration trials were included, involving a total of 37,094 participants. Most trials (64.2%) were of ICI combination therapy. 42.3% of patients were aged≥65 years; 11.1% were aged≥75. No trials specified an upper age limit for eligibility. 98.1% of trials excluded patients with European Cooperative Oncology Group performance status>1. 87.2% of primary efficacy endpoints and 17.9% of secondary efficacy endpoints were reported completely for older adults. Five studies (9.4%) reported baseline characteristics, three (6.1%) reported HRQOL assessments, and four (7.5%) reported toxicity outcomes completely among older subgroups. No trials conducted baseline geriatric assessments or reported geriatric-specific symptoms or quality of life scales. This analysis highlights significant deficits in the enrollment and reporting of older subgroups in pivotal trials of ICI therapy. The findings highlight an urgent need for improved reporting and inclusion standards in clinical trials of ICI to better inform treatment decisions for older adults.
- 1 May 2024
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 20 (9) , 820-827
Hospitalisation and adverse drug events in a geriatric oncology setting: A systematic review of the literature
- 1 May 2024
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 20 (9) , 820-827
Hospitalisation and adverse drug events in a geriatric oncology setting: A systematic review of the literature
- 30 March 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (5) , 101760
Ageing-related considerations for medication used in supportive care in cancer
- 30 March 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (5) , 101760
Ageing-related considerations for medication used in supportive care in cancer
- 17 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (1) , 101669
Corrigendum to “Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis” [Journal of Geriatric Oncology Volume14 (2023)101540]
- 17 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (1) , 101669
Corrigendum to “Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis” [Journal of Geriatric Oncology Volume14 (2023)101540]
- 18 June 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (7) , 1776-1780
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy
Introduction: Medication reconciliation as part of a Comprehensive Geriatric Assessment by a specialist pharmacist is a process that has been shown to be beneficial in terms of medication adherence in patients taking oral anticancer medication and potentially cost-effective in cancer patients. Medication review guidelines in older adults with cancer suggest using polypharmacy (≥ 5 medications) as an indication for medication review in older adults with cancer. Case report: We present a case where a medication review as part of a Comprehensive Geriatric Assessment in the absence of polypharmacy resulted in two pharmacist interventions when standard care resulted in no intervention. A 71-year-old male prescribed capecitabine for rectal cancer had a medication reconciliation done as standard care before starting an oral anticancer medication. He then proceeded to get a medication review as part of a Comprehensive Geriatric Assessment and was deemed to have a potentially excessive anticholinergic burden and underprescribed gastro protection. This case is interesting as it occurred in a patient who would not have met the current inclusion criteria for a medication review as part of a Comprehensive Geriatric Assessment. Management and outcome: As a result of the Comprehensive Geriatric Assessment, a letter was written to the patient's general practitioner, recommending a change to anti-depressant therapy to optimise anticholinergic burden, as well as introducing a proton-pump inhibitor upon completion of the Capecitabine protocol concurrent with radiotherapy, to confer gastro-protection against the antidepressant medication, as per the START criteria. Upon discharge from medical oncology, neither of the changes had been adopted by the patient's general practitioner. This highlights one of the challenges facing clinical pharmacists in an outpatient setting, where evidence-based recommendations are not always implemented as care transitions from tertiary to primary care. Conclusion: Comprehensive Geriatric Assessment is a process that identifies potential issues in older adults with cancer that aren’t identified with standard medication review. This is also evident for medication reviews as part of a Comprehensive Geriatric Assessment, and where resources allow, and recommendations are likely to be accepted, it should be offered to all older adults with cancer. Pharmacists are still faced with challenges in implementing recommendations from medication reviews, particularly in healthcare systems where pharmacist prescribing has yet to be introduced.
- 18 June 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (7) , 1776-1780
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy
Introduction: Medication reconciliation as part of a Comprehensive Geriatric Assessment by a specialist pharmacist is a process that has been shown to be beneficial in terms of medication adherence in patients taking oral anticancer medication and potentially cost-effective in cancer patients. Medication review guidelines in older adults with cancer suggest using polypharmacy (≥ 5 medications) as an indication for medication review in older adults with cancer. Case report: We present a case where a medication review as part of a Comprehensive Geriatric Assessment in the absence of polypharmacy resulted in two pharmacist interventions when standard care resulted in no intervention. A 71-year-old male prescribed capecitabine for rectal cancer had a medication reconciliation done as standard care before starting an oral anticancer medication. He then proceeded to get a medication review as part of a Comprehensive Geriatric Assessment and was deemed to have a potentially excessive anticholinergic burden and underprescribed gastro protection. This case is interesting as it occurred in a patient who would not have met the current inclusion criteria for a medication review as part of a Comprehensive Geriatric Assessment. Management and outcome: As a result of the Comprehensive Geriatric Assessment, a letter was written to the patient's general practitioner, recommending a change to anti-depressant therapy to optimise anticholinergic burden, as well as introducing a proton-pump inhibitor upon completion of the Capecitabine protocol concurrent with radiotherapy, to confer gastro-protection against the antidepressant medication, as per the START criteria. Upon discharge from medical oncology, neither of the changes had been adopted by the patient's general practitioner. This highlights one of the challenges facing clinical pharmacists in an outpatient setting, where evidence-based recommendations are not always implemented as care transitions from tertiary to primary care. Conclusion: Comprehensive Geriatric Assessment is a process that identifies potential issues in older adults with cancer that aren’t identified with standard medication review. This is also evident for medication reviews as part of a Comprehensive Geriatric Assessment, and where resources allow, and recommendations are likely to be accepted, it should be offered to all older adults with cancer. Pharmacists are still faced with challenges in implementing recommendations from medication reviews, particularly in healthcare systems where pharmacist prescribing has yet to be introduced.
- 7 June 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (6) , 101540
Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis
- 7 June 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (6) , 101540
Hospitalization due to adverse drug events in older adults with cancer: A retrospective analysis
- 19 May 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (5) , 101531
Medication assessment in older adults with cancer – Current practices in clinical pharmacy
- 19 May 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (5) , 101531
Medication assessment in older adults with cancer – Current practices in clinical pharmacy